Baird raised the firm’s price target on DexCom (DXCM) to $115 from $104 and keeps an Outperform rating on the shares. The firm said the second half of 2025 will see catalysts as it growth tailwinds continue to build.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: